Greenberg Rachel G, Corneli Amy, Bradley John, Farley John, Jafri Hasan S, Lin Li, Nambiar Sumathi, Noel Gary J, Wheeler Chris, Tiernan Rosemary, Smith P Brian, Roberts Jamie, Benjamin Daniel K
Duke Clinical Research Institute, 2400 Pratt Street, Durham, NC 27705, USA.
Rady Children's Hospital, University of California San Diego, 3020 Children's Way, San Diego, CA 92123, USA.
Contemp Clin Trials Commun. 2017 Nov 26;9:7-12. doi: 10.1016/j.conctc.2017.11.006. eCollection 2018 Mar.
Despite legislation to stimulate pediatric drug development through clinical trials, enrolling children in trials continues to be challenging. Non-investigator (those who have never served as a clinical trial investigator) providers are essential to recruitment of pediatric patients, but little is known regarding the specific barriers that limit pediatric providers from participating in and referring their patients to clinical trials. We conducted an online survey of pediatric providers from a wide variety of practice types across the United States to evaluate their attitudes and awareness of pediatric clinical trials. Using a 4-point Likert scale, providers described their perception of potential barriers to their practice serving as a site for pediatric clinical trials. Of the 136 providers surveyed, 52/136 (38%) had previously referred a pediatric patient to a trial, and only 17/136 (12%) had ever been an investigator for a pediatric trial. Lack of awareness of existing pediatric trials was a major barrier to patient referral by providers, in addition to consideration of trial risks, distance to the site, and time needed to discuss trial participation with parents. Overall, providers perceived greater challenges related to parental concerns and parent or child logistical barriers than study implementation and ethics or regulatory barriers as barriers to their practice serving as a trial site. Providers who had previously been an investigator for a pediatric trial were less likely to be concerned with potential barriers than non-investigators. Understanding the barriers that limit pediatric providers from collaboration or inhibit their participation is key to designing effective interventions to optimize pediatric trial participation.
尽管有立法通过临床试验来刺激儿科药物研发,但让儿童参与试验仍然具有挑战性。非研究者(那些从未担任过临床试验研究者的人)医疗服务提供者对于招募儿科患者至关重要,但对于限制儿科医疗服务提供者参与临床试验并将其患者转介至临床试验的具体障碍,我们却知之甚少。我们对来自美国各种不同执业类型的儿科医疗服务提供者进行了一项在线调查,以评估他们对儿科临床试验的态度和认知。医疗服务提供者使用4级李克特量表描述了他们对于其执业机构作为儿科临床试验场所的潜在障碍的看法。在接受调查的136名医疗服务提供者中,52/136(38%)曾将一名儿科患者转介至一项试验,而只有17/136(12%)曾担任过儿科试验的研究者。除了考虑试验风险、到试验地点的距离以及与家长讨论试验参与所需的时间外,对现有儿科试验缺乏认知是医疗服务提供者将患者转介的一个主要障碍。总体而言,医疗服务提供者认为,与家长的担忧以及家长或儿童的后勤障碍相比,研究实施、伦理或监管障碍对其执业机构作为试验场所来说是更大的障碍。曾担任过儿科试验研究者的医疗服务提供者比非研究者更不太可能担心潜在障碍。了解限制儿科医疗服务提供者进行合作或阻碍其参与的障碍,是设计有效干预措施以优化儿科试验参与度的关键。